Dates
When does the Virtual Hearing in Vienna take place?
March 27 - April 1, 2021 (p. 1)
Who signed the Agreement on behalf of both CLM and RSP1?
Ms Alexandra Flemming for CLM and Mr Paul Metschnikow for RSP1 (p. 17)
What is the main focus of CLM's business?
Development of vaccines for respiratory diseases caused by viruses (p. 4)
What is the Effective Date of the Agreement between CLM and RSP1?
1st January 2019 (p. 11)
Who represents CLM and both RSPs in the arbitral proceedings?
Mr Joseph Langweiler for CLM and Ms Julia Clara Fasttrack for RSPs (p. 37)
In which clause is the Arbitration Agreement embodied?
Clause 14.1 (p. 16 + 33)
When did CLM start the research on the vaccine against Covid-19?
Early February 2020 (p. 7)
Name at least 2 of the appointed arbitrators.
Prof. Francoise Sinoussi (presiding)
Ilja Ehrlich
Dr. Youtu You (p. 43)
How much was the Upfront Payment made by CLM under the Agreement?
2,500,000 EUR (p. 13)
When was the dispute between Ross Pharmaceuticals and RSP2 firstly mentiond in Biopharma Science journal?
14th December 2018 (p. 18)
Who is the Chief Financial Officer of RespiVac?
Rosaly Hübner (p. 21)
Against which virus causing respiratory diseases did Ross Pharmaceuticals lead the research before SARS-Cov-2?
MERS-Coronavirus (p. 27)
When was the production of the GorAdCam viral vectors under GMP-conditions officially announced by CamVir?
28th November 2018 (p. 10)
Who announced the acquisition of RespiVac by Khorana Lifescience at the press conference?
Prof S. E. Luria (p. 29)
In what countries are all subjects at question seated? (There are 6 of them).
RespiVac - Mediterraneo (p. 4)
CamVir + VectorVir - Equatoriana (p. 4)
Ross Pharmaceuticals - Danubia (p. 32)
Khorana Lifescience - Danubia (p. 25)
Roctis Group - Danubia (p. 36)